NOVO.B.DK

284.6

-2.38%↓

GMAB.DK

1,637

-3.85%↓

COLO.B.DK

381.4

-3.78%↓

HLUNB.DK

42.94

-0.83%↓

AMBUB.DK

65.25

-2.39%↓

NOVO.B.DK

284.6

-2.38%↓

GMAB.DK

1,637

-3.85%↓

COLO.B.DK

381.4

-3.78%↓

HLUNB.DK

42.94

-0.83%↓

AMBUB.DK

65.25

-2.39%↓

NOVO.B.DK

284.6

-2.38%↓

GMAB.DK

1,637

-3.85%↓

COLO.B.DK

381.4

-3.78%↓

HLUNB.DK

42.94

-0.83%↓

AMBUB.DK

65.25

-2.39%↓

NOVO.B.DK

284.6

-2.38%↓

GMAB.DK

1,637

-3.85%↓

COLO.B.DK

381.4

-3.78%↓

HLUNB.DK

42.94

-0.83%↓

AMBUB.DK

65.25

-2.39%↓

NOVO.B.DK

284.6

-2.38%↓

GMAB.DK

1,637

-3.85%↓

COLO.B.DK

381.4

-3.78%↓

HLUNB.DK

42.94

-0.83%↓

AMBUB.DK

65.25

-2.39%↓

Home・Elenco Azioni・Zealand Pharma A-S

Zealand Pharma A-S

Chiusa

311.6 -3.35

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

309.5

Massimo

323.9

Metriche Chiave
By Trading Economics
Entrata	-15M -394M
Vendite	-35M 34M
P/E Media del settore	3.61 50.102
EPS	-5.58
Margine di Profitto	-1,158.824
Dipendenti	544
EBITDA	-26M -529M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+25.15% upside

Dividendi
By Dow Jones
Utili prossimi	13 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.6B 23B
Apertura precedente	314.95
Chiusura precedente	311.6

Zealand Pharma A-S Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mar 2026, 09:24 UTC

I principali Market Mover

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

1 ott 2025, 08:54 UTC

I principali Market Mover

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

6 mar 2026, 07:22 UTC

Discorsi di Mercato

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

Confronto tra pari

Modifica del prezzo

Zealand Pharma A-S Previsione

Obiettivo di Prezzo

By TipRanks

25.15% in crescita

Previsioni per 12 mesi

Media 270.582 DKK 25.15%

Alto 270.568 DKK

Basso 270.568 DKK

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zealand Pharma A-S - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Zealand Pharma A-S - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.